Clinical trial
Beta Alethine in Treating Patients With Waldenstrom's Macroglobulinemia
NCT00041379 · LifeTime Pharmaceuticals, Industry · Unknown status
Key facts
| NCT number | NCT00041379 |
|---|---|
| Title | Beta Alethine in Treating Patients With Waldenstrom's Macroglobulinemia |
| Official title | Phase I/II Study to Assess the Safety and Efficacy of Low Doses of Beta LT in Patients With Waldenstrom's Macroglobulinemia |
| Lead sponsor | LifeTime Pharmaceuticals, Industry |
| Status | Unknown status |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | beta alethine |
| Start date | Mar 1, 2002 |
| First posted | Jan 27, 2003 |
| Last update posted | Dec 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: